GlassScriptPhysician profile
Priyanka Pathak
NPI 1417189440
$4,271.06
in general payments reported to CMS, 2019-2025
49 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2023: $125 · 2024: $2,140 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,022 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,021.75 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $352.46 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $352.02 | 2024-2025 | Tagrisso, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $283.23 | 2024-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $279.90 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $250.68 | 2024-2025 | |
| Daiichi Sankyo INC. | $226.97 | 2023-2025 | Enhertu, Injectafer |
| Genentech USA, INC. | $219.16 | 2024-2025 | Tecentriq, Venclexta, Phesgo |
| Celgene Corporation | $206.02 | 2024 | Reblozyl, Pomalyst |
| Sobi, INC | $154.73 | 2024 | |
| Jazz Pharmaceuticals INC. | $151.10 | 2024-2025 | |
| Glaxosmithkline, LLC. | $139.14 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $134.98 | 2024-2025 | Fruzaqla, Iclusig, Alunbrig |
| Stemline Therapeutics INC. | $132.06 | 2024-2025 | Orserdu, Elzonris |
| Puma Biotechnology, INC. | $104.23 | 2024-2025 | |
| Pharmaessentia USA Corporation | $99.50 | 2024-2025 | Besremi |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyanka Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.